The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Association of cardiac biomarkers and AEs with carfilzomib-containing regimens for high-risk NDMM
Lisa Leypoldt, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, provides insight into the key findings of a study investigating the association of cardiac biomarkers and adverse events (AEs) with a carfilzomib-containing quadruplet regimen in patients with high-risk newly diagnosed (ND) multiple myeloma (MM). Dr Leypoldt highlights the importance of assessing patients for the risk of cardiovascular adverse events at baseline prior to initiating a carfilzomib-containing therapy but also emphasizes that patients should be closely monitored throughout their treatment. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
